Summit Therapeutics (SUMM) is a small-cap biotech company with two drugs in clinical trials at either end of the new drugs space: a low risk, lower reward antibiotic and a high risk, higher reward Duchenne Muscular Dystrophy cure. Does this make it an ideal biotech investment? Megan Boxall investigates.
For all our other podcasts, including the latest IC Questions special on profit warnings in 2017 and more episdoes of Boardroom Talk, go to www.investorschronicle.co.uk/podcast
